Published in
Taylor and Francis Group, OncoImmunology, 12(4), p. e1054600
DOI: 10.1080/2162402x.2015.1054600
Links
- ORCID
- Taylor and Francis Group | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Melanoma targeting with the loco-regional chemotherapeutic, Melphalan: From cell death to immunotherapeutic efficacy
Journal article published in 2015 by
Aleksandra Maria Dudek-Perić,
Jakub Gołąb,
Abhishek D. Garg 
,
Patrizia Agostinis
,
Patrizia Agostinis
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
All immunoregulatory chemotherapeutics are chiefly applied in a systemic setting for anticancer therapy. However, immune responses following loco-regional application of chemotherapy may differ from those after systemic application. We recently found that Melphalan, a prototypical loco-regionally applied chemotherapeutic agent, exhibits the ability to increase the immunogenicity of dying melanoma cells.